Atlas Trials

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Clinical trial NCT03794336 · COMPLETED

Trial details

NCT number
NCT03794336
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Type 2 Diabetes Mellitus
Start date
2019-06-29
Primary completion
2020-12-14
Enrollment
1293

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.